Chronic administration of DSP‐7238, a novel, potent, specific and substrate‐selective DPP IV inhibitor, improves glycaemic control and <i>β</i> ‐cell damage in diabetic mice

Abstract

We have shown in this study that DSP-7238 is a potent DPP IV inhibitor that has high specificity for DPP IV and substrate selectivity against GLP-1. We have also found that chronic treatment with DSP-7238 improves glycaemic control and ameliorates beta-cell damage in a mouse model with impaired insulin sensitivity and secretion. These findings indicate that DSP-7238 may be a new therapeutic agent for the treatment of type 2 diabetes.